Nasal spray market heats up as Covid-19 curbs ease, people return to work

Glenmark launches 1st commercially available spray, smaller firms to follow

Nasal spray market heats up as Covid-19 curbs ease, people return to work
Premium

Sohini Das Mumbai
As Covid-19 restrictions ease and people return to work, drug firms see an opportunity in both the over-the-counter (OTC) and prescription space for germ-killing nasal sprays. While big firms like Glenmark have come up with products like nitric oxide nasal sprays, smaller ones like Strassenburg too have launched ayurvedic nasal and mouth-spray combinations.

On Wednesday, Mumbai-headquartered Glenmark launched nitric oxide nasal spray (NONS), under the brand name FabiSpray, for treating adult Covid-19 patients. NONS is designed to kill the coronavirus in the upper airways, preventing it from incubating and spreading to the lungs.

The spray’s phase-3 trial in India demonstrated a 94 per cent reduction in viral load in 24 hours, and 99 per cent in 48 hours. NONS has

First Published: Feb 10 2022 | 06:12 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com